ROYALTY PHARMA PLC- CL A (RPRX)       42.24  +0.31 (+0.74%)

42.24  +0.31 (+0.74%)

GB00BMVP7Y09 - Common Stock


Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to RPRX. RPRX was compared to 257 industry peers in the Pharmaceuticals industry. RPRX has a medium financial health rating, its profitability is only medium as well. RPRX has a correct valuation and a medium growth rate.




Profitability

Profitability Rating

6

RPRX's Return On Assets of 2.87% is amongst the best returns of the industry. RPRX outperforms 87% of its industry peers. The industry average Return On Assets is -41.45%.
RPRX's Profit Margin of 22.55% is amongst the best returns of the industry. RPRX outperforms 92% of its industry peers. The industry average Profit Margin is -108.01%.

RPRX has a Piotroski-F score of 4.00. This indicates an average health and profitability for RPRX.
RPRX has a Return On Equity of 8.24%. This is below the industry average of 20.44%.
VS Industry

ROA (2.87%) VS Industry: 87% outperformed.

-1,292.14
111.39

ROE (8.24%) VS Industry: 29% outperformed.

1.38
176.97

Profit Margin (22.55%) VS Industry: 92% outperformed.

-53,337.68
1,968.82

Valuation

Valuation Rating

6

The Forward Price/Earnings Ratio of 11.91 indicates a rather cheap valuation of RPRX.
RPRX's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The Price/Earnings Ratio is 14.52, which indicates a correct valuation of RPRX.

RPRX's Price/Earning Ratio is in line with the industry average which is at 14.29.
With a price book ratio of 3.03, RPRX is valued correctly.
When comparing the price book ratio of RPRX to the average industry price book ratio of 1.43, RPRX is valued more expensive than its industry peers.
VS Industry

Price/Earnings (14.52) VS Industry: 44% outperformed.

85.27
0.75

Price/Book (3.03) VS Industry: 29% outperformed.

302.05
0.09

Growth

Growth Rating

5

RPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.18%, which is quite impressive.
Based on estimates for the next 5 years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.15% on average per year.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Looking at the last year, RPRX shows a decrease in Revenue. The Revenue has decreased by -1.69% in the last year.

Measured over the past 5 years, RPRX shows a small growth in Revenue. The Revenue has been growing by 8.45% on average per year.
Based on estimates for the next 5 years, RPRX will show a small growth in Revenue. The Revenue will grow by 6.87% on average per year.
The Revenue growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.
RPRX shows a very negative growth in Earnings Per Share. Measured over the last 5 years, the EPS has been decreasing by -13.57% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A -13.57% 70.18% 37.55% 26.12% 21.58% 18.15%
RevenueN/A 8.45% -1.69% 8.62% 7.42% 9.6% 6.87%

Health

Health Rating

4

A Current Ratio of 2.07 indicates that RPRX has no problem at all paying its short term obligations.
A Quick Ratio of 2.07 indicates that RPRX has no problem at all paying its short term obligations.
The Altman-Z score of RPRX is much better than the industry average of -0.53.
RPRX has a Piotroski-F score of 4.00. This indicates an average health and profitability for RPRX.

Compared to an average industry Current Ratio of 3.51, RPRX is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 2.88, RPRX is worse placed to pay its short term obligations than its industry peers.
RPRX has one of the worst Debt to Equity ratios in its industry. 88% of its industry peers require less debt for financing their operations.
RPRX has an Altman-Z score of 1.59. This is a bad value and indicates that RPRX is not financially healthy and even has some risk of bankruptcy.
VS Industry

Debt/Equity (0.99) VS Industry: 12% outperformed.

59.36
0.00

Quick Ratio (2.07) VS Industry: 37% outperformed.

-2.73
76.82

Current Ratio (2.07) VS Industry: 28% outperformed.

0.09
76.82

Altman-Z (1.59) VS Industry: 66% outperformed.

-231.44
114.17

Dividend

Dividend Rating

1

With a Yearly Dividend Yield of 1.77%, RPRX has a reasonable but not impressive dividend return.
RPRX's Dividend Yield is slightly below the industry average, which is at 2.73.
RPRX's Dividend Yield is slightly below the S&P500 average, which is at 2.43.

RPRX pays out 63.68% of its income as dividend. This is not a sustainable payout ratio.
RPRX is new to the dividend game and has less than 3 years of track record.
VS Industry

Dividend Yield (1.77%) VS Industry: 22% outperformed.

0.67
7.18
RPRX Daily chart

ROYALTY PHARMA PLC- CL A42.24

NASDAQ:RPRX (12/7/2022, 12:41:06 PM)+0.31 (+0.74%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) 02-13 2023-02-13
Ins Owners 0.1% Inst Owners 67.07%
Market Cap 18.63B Analysts 81.11
Valuation
PE 14.52 Fwd PE 11.91
PEG (NY) 0.39 PEG (5Y) N/A
P/S 8.29 P/B 3.03
EV/EBITDA N/A
Dividend
Dividend Yield 1.77% Dividend Growth N/A
DP 63.68% Ex-Date 11-17 2022-11-17 (0.19)
Growth
EPS 1Y 70.18% EPS 3Y -13.57%
EPS 5Y N/A EPS growth Q2Q 323.53%
EPS Next Y 37.55% EPS Next 2Y 26.12%
EPS Next 3Y 21.58% EPS Next 5Y 18.15%
Revenue growth 1Y -1.69% Revenue growth 3Y 8.45%
Revenue growth 5Y N/A Revenue growth Q2Q -2.1%
Revenue Next Year 8.62% Revenue Next 2Y 7.42%
Revenue Next 3Y 9.6% Revenue Next 5Y 6.87%
Health
Current Ratio 2.07 Quick Ratio 2.07
Altman-Z 1.59 F-Score 4
Debt/Equity 0.99 WACC 8.26%
ROIC/WACC 0.63
Profitability
ROA 2.87% ROE 8.24%
ROICexgc 5.2% ROIC 4.5%
PM 22.55% OM 41.97%
Asset Turnover 0.13

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA